Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab

Baumal, Caroline R.; Spaide, Richard F.; Vajzovic, Lejla; Freund, K. Bailey; Walter, Scott D.; John, Vishak J.; Rich, Ryan; Chaudhry, Nauman; Lakhanpal, Rohit R.; Oellers, Patrick; Leveque, Thellea K.; Rutledge, Bryan K.; Chittum, Mark E.; Bacci, Tommaso; Enríquez, Ana Bety; Sund, Newman J.; Subong, Eric N.P.; Albini, Thomas A.

doi:10.1016/j.ophtha.2020.04.017

Cited by 233 publications

(307 citation statements)

References 23 publications

Supporting

Mentioning

269

Contrasting

Unclassified

Order By: Relevance

“…BARV is an inflammatory AE that is specific to brolucizumab [57]. Given that brolucizumab only received FDA approval in October 2019, it is unsurprising that this newly recognized entity remains poorly understood.…”

Section: Brolucizumab-associated Retinal Vasculitismentioning

confidence: 99%

Inflammatory Complications of Intravitreal Anti-VEGF Injections

Cox

Eliott

Sobrin

2021

JCM

View full text Add to dashboard Cite

Intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) agents is a commonly used therapy for numerous retinal diseases. The most commonly used of these medications are bevacizumab, ranibizumab, aflibercept, and brolucizumab. However, intravitreal administration of these agents is also associated with several inflammatory and non-inflammatory adverse events. The three inflammatory adverse events are sterile intraocular inflammation, brolucizumab-associated retinal vasculitis, and post-injection endophthalmitis. This narrative review summarizes the current literature regarding these conditions, including their epidemiology, presentation, management, outcomes, and pathogenesis. The inflammatory adverse events also share a number of overlapping features, which can make them difficult to discern from one another in a clinical context. This review discusses certain distinguishing features of these conditions that may aid providers in discerning between them and establishing the correct diagnosis.

show abstract

Section: Brolucizumab-associated Retinal Vasculitismentioning

confidence: 99%

Inflammatory Complications of Intravitreal Anti-VEGF Injections

Cox

Eliott

Sobrin

2021

JCM

View full text Add to dashboard Cite

show abstract

“…Although the initial results with brolucizumab have been promising, the drug's safety is currently under review due to reports of clinically significant intraocular inflammation and occlusive retinal vasculitis associated with the study drug in the HAWK and HARRIER studies as well as in patients with neovascular AMD treated with brolucizumab after the drug was approved by the FDA [26][27][28][29][30]. In addition, Novartis, the manufacturer of brolucizumab, has also reported the occurrence of vitritis and retinal vasculitis in subjects with DME being treated with RTH 258 in current studies [31,32].…”

Section: Brolucizumabmentioning

confidence: 99%

RETRACTED ARTICLE: Pharmacological agents in development for diabetic macular edema

et al. 2020

View full text Add to dashboard Cite

Background: Diabetic macular edema (DME) is the leading cause of visual loss in patients with diabetic retinopathy. There has been a paradigm shift in the treatment of DME since the advent of anti-vascular endothelial growth factor (anti-VEGF) therapy. The safety and efficacy of anti-VEGF therapy has been well established. Although efficacious, currently approved anti-VEGF agents are associated with certain limitations, which include, among others: frequent need for injections, high treatment cost and variable response to treatment. These challenges have led to an active search for more novel agents that may be able to overcome these limitations. Areas covered: The index review focuses on novel treatment agents that target various pathways in patients with DME. These agents are used either as monotherapy or in combination with other agents in the management of DME. Drugs discussed include novel anti-VEGF inhibitors, TIE-2 receptor modulators, integrin peptide inhibitors, rho kinase inhibitors, and future therapies such as neuroprotection and gene therapy. Conclusions: The future of investigational pharmacological therapy appears promising for patients with DME. Results from early clinical trials indicate that newer agents highlighted in the study may be safe and efficacious treatment options for patients with DME. However, data from large multicenter clinical trials need to be analyzed before these agents can be incorporated into clinical practice.

show abstract

“…14 Retinal vasculitis (mostly occlusive) has also been reported in patients treated with the anti-VEGF brolucizumab. 23 There were no new cases of retinal vasculitis in the abicipar treatment groups during the second year of the CEDAR/SEQUOIA study.…”

Section: Discussionmentioning

confidence: 88%

Two-Year Results of the Phase 3 Randomized Controlled Study of Abicipar in Neovascular Age-Related Macular Degeneration

et al. 2021

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab

Cited by 233 publications

References 23 publications

Inflammatory Complications of Intravitreal Anti-VEGF Injections

Inflammatory Complications of Intravitreal Anti-VEGF Injections

RETRACTED ARTICLE: Pharmacological agents in development for diabetic macular edema

Two-Year Results of the Phase 3 Randomized Controlled Study of Abicipar in Neovascular Age-Related Macular Degeneration

Contact Info

Product

Resources

About